Madrigal Pharmaceuticals, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Madrigal Pharmaceuticals, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Madrigal Pharmaceuticals, Inc. do? Business model and key facts
Get the full picture of Madrigal Pharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 528
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Stocks related to Madrigal Pharmaceuticals, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Madrigal Pharmaceuticals, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Madrigal Pharmaceuticals, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
